Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively
Associations between achievement of these specified clinical response
All patients who reached the following specified clinical response
Observed case data are reported.
Achievement of higher ASAS response levels was also associated
•
improvements in physical function and health-related quality of life
To examine how achievement of increasingly stringent clinical
Objective
Presented at ACR Convergence 2022  |  Philadelphia, Pennsylvania, USA  |  November 10–14 2022
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity is Associated with Greater
Figure 2
Figure 1A
sequentially greater mean (95% confidence interval) improvements
reduced physical function and HRQoL (pain, fatigue, and physical limitation
time since diagnosis, indicating similar burden of symptom severity,
standardized measure, higher score reflects better HRQoL) and HRQoL
BASFI: scored from 0 [best] to 18 [worst]) were assessed. It should be
ASQoL: score from 0 [best] to 100 [worst] was used.
ASDAS: change from baseline; ASDAS-40: clinical improvement 40%; change
no radiographic (n=452) and BE MODUS 2 (n=1473) radiographic axial (n=446), in patients with ankylosing spondylitis (axSpA).
Here, we present a post hoc analysis of Week 16 results from these
3 phases, and review the full spectrum of axSpA independent of treatment arm.
Methods
All patients who reached the following specified clinical response
criteria/levels of disease activity and improvements in patient-reported

Baseline
Week 0
BE MOBILE 1 (nr-axSpA)
BE MOBILE 2 (r-axSpA)
Table 1
Patient demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Age, years</th>
<th>Sex, male</th>
<th>14A-ASD positive</th>
<th>Symptom duration, years</th>
<th>Vertebrae radiographic of axSpA, years</th>
<th>ASDAS</th>
<th>ASDAS-CII</th>
<th>CRP</th>
<th>hsCRP</th>
<th>ID</th>
<th>IL</th>
<th>vHDA</th>
<th>LDA</th>
<th>CdlL</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 (41–51)</td>
<td>118 (45–54)</td>
<td>107 (75–179)</td>
<td>9.5 (3.8)</td>
<td>3.8 (1.9)</td>
<td>3.9 (0.7)</td>
<td>6.0 (2.1)</td>
<td>6.5 (2.1)</td>
<td>6.4 (3.1)</td>
<td>6.4 (3.1)</td>
<td>6.4 (3.1)</td>
<td>6.4 (3.1)</td>
<td>6.4 (3.1)</td>
<td></td>
</tr>
</tbody>
</table>

Table of data reported above. Jaccoud arthritis was included. Patients were stratified into three mutually exclusive groups based on 2013 clinical response criteria. One site did not achieve 2012 BASDAI <4.0. Mean values of 2013 BASDAI >2.1 are assessed at Week 0.

Conclusions
Patients with nr-axSpA and r-axSpA who achieved increasingly stringent clinical response criteria and lower levels of disease activity at Week 16 reported sequentially greater improvements in physical function and HRQoL. Similar amplitudes of improvement for each response level were observed across the axSpA disease spectrum.